Viral Vaccines Market Size, Industry Demand, Forecast to 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Viral Vaccines Market Size Analysis

Global Viral Vaccines Market Introduction
By Types
1. Introduction
  1. Types By Value
2. Live attenuated vaccines
  1. By Value
3. Inactivated vaccines
  1. By Value
4. Sub-Unit viral vaccines
  1. By Value
By Consumer groups
1. Introduction
  1. Consumer groups By Value
2. Pediatric
  1. By Value
3. Adults
  1. By Value
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Cancer
  1. By Value
3. Influenza
  1. By Value
4. Human Papilloma Virus
  1. By Value
5. Rota Virus
  1. By Value
6. Poliomyelitis
  1. By Value
7. Hepatitis
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. By Route of Administration By Value
2. Parenteral
  1. By Value
3. Oral
  1. By Value

North America Market Analysis

Introduction
By Types
1. Introduction
  1. Types By Value
2. Live attenuated vaccines
  1. By Value
3. Inactivated vaccines
  1. By Value
4. Sub-Unit viral vaccines
  1. By Value
By Consumer groups
1. Introduction
  1. Consumer groups By Value
2. Pediatric
  1. By Value
3. Adults
  1. By Value
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Cancer
  1. By Value
3. Influenza
  1. By Value
4. Human Papilloma Virus
  1. By Value
5. Rota Virus
  1. By Value
6. Poliomyelitis
  1. By Value
7. Hepatitis
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. By Route of Administration By Value
2. Parenteral
  1. By Value
3. Oral
  1. By Value
U.S.
1. By Types
  1. Introduction
    1. Types By Value
  2. Live attenuated vaccines
    1. By Value
  3. Inactivated vaccines
    1. By Value
  4. Sub-Unit viral vaccines
    1. By Value
2. By Consumer groups
  1. Introduction
    1. Consumer groups By Value
  2. Pediatric
    1. By Value
  3. Adults
    1. By Value
3. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Cancer
    1. By Value
  3. Influenza
    1. By Value
  4. Human Papilloma Virus
    1. By Value
  5. Rota Virus
    1. By Value
  6. Poliomyelitis
    1. By Value
  7. Hepatitis
    1. By Value
  8. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. By Route of Administration By Value
  2. Parenteral
    1. By Value
  3. Oral
    1. By Value
Canada

Europe Market Analysis

Introduction
By Types
1. Introduction
  1. Types By Value
2. Live attenuated vaccines
  1. By Value
3. Inactivated vaccines
  1. By Value
4. Sub-Unit viral vaccines
  1. By Value
By Consumer groups
1. Introduction
  1. Consumer groups By Value
2. Pediatric
  1. By Value
3. Adults
  1. By Value
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Cancer
  1. By Value
3. Influenza
  1. By Value
4. Human Papilloma Virus
  1. By Value
5. Rota Virus
  1. By Value
6. Poliomyelitis
  1. By Value
7. Hepatitis
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. By Route of Administration By Value
2. Parenteral
  1. By Value
3. Oral
  1. By Value
U.K.
1. By Types
  1. Introduction
    1. Types By Value
  2. Live attenuated vaccines
    1. By Value
  3. Inactivated vaccines
    1. By Value
  4. Sub-Unit viral vaccines
    1. By Value
2. By Consumer groups
  1. Introduction
    1. Consumer groups By Value
  2. Pediatric
    1. By Value
  3. Adults
    1. By Value
3. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Cancer
    1. By Value
  3. Influenza
    1. By Value
  4. Human Papilloma Virus
    1. By Value
  5. Rota Virus
    1. By Value
  6. Poliomyelitis
    1. By Value
  7. Hepatitis
    1. By Value
  8. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. By Route of Administration By Value
  2. Parenteral
    1. By Value
  3. Oral
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Types
1. Introduction
  1. Types By Value
2. Live attenuated vaccines
  1. By Value
3. Inactivated vaccines
  1. By Value
4. Sub-Unit viral vaccines
  1. By Value
By Consumer groups
1. Introduction
  1. Consumer groups By Value
2. Pediatric
  1. By Value
3. Adults
  1. By Value
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Cancer
  1. By Value
3. Influenza
  1. By Value
4. Human Papilloma Virus
  1. By Value
5. Rota Virus
  1. By Value
6. Poliomyelitis
  1. By Value
7. Hepatitis
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. By Route of Administration By Value
2. Parenteral
  1. By Value
3. Oral
  1. By Value
China
1. By Types
  1. Introduction
    1. Types By Value
  2. Live attenuated vaccines
    1. By Value
  3. Inactivated vaccines
    1. By Value
  4. Sub-Unit viral vaccines
    1. By Value
2. By Consumer groups
  1. Introduction
    1. Consumer groups By Value
  2. Pediatric
    1. By Value
  3. Adults
    1. By Value
3. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Cancer
    1. By Value
  3. Influenza
    1. By Value
  4. Human Papilloma Virus
    1. By Value
  5. Rota Virus
    1. By Value
  6. Poliomyelitis
    1. By Value
  7. Hepatitis
    1. By Value
  8. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. By Route of Administration By Value
  2. Parenteral
    1. By Value
  3. Oral
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Types
1. Introduction
  1. Types By Value
2. Live attenuated vaccines
  1. By Value
3. Inactivated vaccines
  1. By Value
4. Sub-Unit viral vaccines
  1. By Value
By Consumer groups
1. Introduction
  1. Consumer groups By Value
2. Pediatric
  1. By Value
3. Adults
  1. By Value
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Cancer
  1. By Value
3. Influenza
  1. By Value
4. Human Papilloma Virus
  1. By Value
5. Rota Virus
  1. By Value
6. Poliomyelitis
  1. By Value
7. Hepatitis
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. By Route of Administration By Value
2. Parenteral
  1. By Value
3. Oral
  1. By Value
UAE
1. By Types
  1. Introduction
    1. Types By Value
  2. Live attenuated vaccines
    1. By Value
  3. Inactivated vaccines
    1. By Value
  4. Sub-Unit viral vaccines
    1. By Value
2. By Consumer groups
  1. Introduction
    1. Consumer groups By Value
  2. Pediatric
    1. By Value
  3. Adults
    1. By Value
3. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Cancer
    1. By Value
  3. Influenza
    1. By Value
  4. Human Papilloma Virus
    1. By Value
  5. Rota Virus
    1. By Value
  6. Poliomyelitis
    1. By Value
  7. Hepatitis
    1. By Value
  8. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. By Route of Administration By Value
  2. Parenteral
    1. By Value
  3. Oral
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Types
1. Introduction
  1. Types By Value
2. Live attenuated vaccines
  1. By Value
3. Inactivated vaccines
  1. By Value
4. Sub-Unit viral vaccines
  1. By Value
By Consumer groups
1. Introduction
  1. Consumer groups By Value
2. Pediatric
  1. By Value
3. Adults
  1. By Value
By Disease Indication
1. Introduction
  1. Disease Indication By Value
2. Cancer
  1. By Value
3. Influenza
  1. By Value
4. Human Papilloma Virus
  1. By Value
5. Rota Virus
  1. By Value
6. Poliomyelitis
  1. By Value
7. Hepatitis
  1. By Value
8. Others
  1. By Value
By Route of Administration
1. Introduction
  1. By Route of Administration By Value
2. Parenteral
  1. By Value
3. Oral
  1. By Value
Brazil
1. By Types
  1. Introduction
    1. Types By Value
  2. Live attenuated vaccines
    1. By Value
  3. Inactivated vaccines
    1. By Value
  4. Sub-Unit viral vaccines
    1. By Value
2. By Consumer groups
  1. Introduction
    1. Consumer groups By Value
  2. Pediatric
    1. By Value
  3. Adults
    1. By Value
3. By Disease Indication
  1. Introduction
    1. Disease Indication By Value
  2. Cancer
    1. By Value
  3. Influenza
    1. By Value
  4. Human Papilloma Virus
    1. By Value
  5. Rota Virus
    1. By Value
  6. Poliomyelitis
    1. By Value
  7. Hepatitis
    1. By Value
  8. Others
    1. By Value
4. By Route of Administration
  1. Introduction
    1. By Route of Administration By Value
  2. Parenteral
    1. By Value
  3. Oral
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Viral Vaccines Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Merck & Co., Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
GSK plc
Sanofi
CureVac SE
Pfizer Inc.
Moderna, Inc
Johnson & Johnson Services, Inc.
AstraZeneca
Dynavax Technologies
Zydus Group
Biological E Limited.
Panacea Biotec Limited
CSL
Serum Institute of India Pvt. Ltd.
Bharat Biotech.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment